Clinical Trial Update: 14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection [Phase 4]

View source ↗

Summary

Phase 4 trial completed evaluating a 14-day susceptibility-guided bismuth quadruple therapy for multidrug-resistant Helicobacter pylori infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Helicobacter Pylori Infection

Drugs mentioned

• Susceptibility-guided bismuth quadruple therapy

Snippet

Sponsor: National Cheng-Kung University Hospital | Conditions: Helicobacter Pylori, Drug Resistance, Multiple | Phase 4 | Status: COMPLETED